ReviewNeuroimaging clinics of North America2020
Neuroimaging in Schizophrenia.
Review in Neuroimaging clinics of North America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 138 citations in OpenAlex.
- Toward precision medicine: can neuroimaging prospectively predict early treatment outcomes in schizophrenia spectrum disorders? A systematic review and meta-analysis.European archives of psychiatry and clinical neuroscience · 2026Review
- Decision processes in 3D structural MRI schizophrenia classification evaluated with saliency maps.Scientific reports · 2026Article
- Explainable AI based ensemble model for the identification of Schizophrenia prodromal phase.Scientific reports · 2026Article
- Hypothalamic subunit volumes and relations to violence and psychopathy in male offenders with or without a psychotic disorder.European archives of psychiatry and clinical neuroscience · 2026Article
- The plasma-derived exosomal Gomafu levels are associated with psychopathological symptoms and symptomatic remission in drug-naïve patients with first-episode schizophrenia.European archives of psychiatry and clinical neuroscience · 2026Article
- Genetic Variations in the Dopaminergic Signaling Pathways and Their Implications for Antipsychotics Pharmacogenetics.Journal of molecular neuroscience : MN · 2026Review
- Non-coding RNA in extracellular vesicles and the occurrence and progression of psychiatric disorders: A narrative review.World journal of psychiatry · 2026Review
- Schizophrenia Pathophysiology: Neurotransmitter Dysfunctions and Biomarker Frontiers.Current topics in medicinal chemistry · 2026Review
- Multimodal neuroimaging alterations in schizophrenia model rats and the modulatory effects of risperidone: a pilot study.Frontiers in psychiatry · 2026Article
- Machine learning-based morphological brain analysis in schizophrenia and unaffected siblings: a multisite study of potential risk markers.Frontiers in neuroscience · 2026Article
- Fad diets, schizophrenia, and politics: An internet frenzy that highlights broader concerns.PLOS mental health · 2026Article
- Polygenic risk for schizophrenia is associated with white matter microstructure, cognitive and mental health.Schizophrenia (Heidelberg, Germany) · 2025Article
- Disrupted genes and pathways in schizophrenia: a robust analysis of the brain and blood.BMC psychiatry · 2025Article
- Membrane Trafficking in Psychiatric Disorders: Bridging Cellular Dysfunction and Mental Health-A Narrative Review.Molecular neurobiology · 2025Review
- Serum lipid metabolic characteristics and potential biomarkers in first-episode schizophrenia.BMC psychiatry · 2025Article
- Blood‑brain barrier dysfunction in schizophrenia: Mechanisms and implications (Review).International journal of molecular medicine · 2025Review
- Schizophrenia and Neurodevelopment: Insights From Connectome Perspective.Schizophrenia bulletin · 2025Review
- The Psychosis MRI Shared Data Resource (Psy-ShareD).Human brain mapping · 2025Article
- Neuroimaging in post-traumatic stress disorder: a narrative review.Archives of medical science : AMS · 2025Article
- Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 4 countries.
Funding
Abstract
Schizophrenia is a chronic psychotic disorder with a lifetime prevalence of about 1%. Onset is typically in adolescence or early adulthood; characteristic symptoms include positive symptoms, negative symptoms, and impairments in cognition. Neuroimaging studies have shown substantive evidence of brain structural, functional, and neurochemical alterations that are more pronounced in the association cortex and subcortical regions. These abnormalities are not sufficiently specific to be of diagnostic value, but there may be a role for imaging techniques to provide predictions of outcome. Incorporating multimodal imaging datasets using machine learning approaches may offer better diagnostic and predictive value in schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.